公开(公告)号：US12059454B2

公开(公告)日：2024-08-13

申请号：US17591151

申请日：2022-02-02

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

发明人： Henry Daniell ,  Qiuhong Li ,  Mohan K. Raizada

IPC分类号： C12N15/82 ,  A61K9/00 ,  A61K9/16 ,  A61K9/19 ,  A61K9/50 ,  A61K36/23 ,  A61K36/28 ,  A61K36/31 ,  A61K38/16 ,  A61K38/22 ,  A61K38/48 ,  A61K47/64 ,  A61K47/65 ,  C07K14/28 ,  C12N9/48

CPC分类号： A61K38/4813 ,  A61K9/0053 ,  A61K9/1664 ,  A61K9/19 ,  A61K9/5063 ,  A61K36/23 ,  A61K36/28 ,  A61K36/31 ,  A61K38/164 ,  A61K38/22 ,  A61K47/6415 ,  A61K47/65 ,  C07K14/28 ,  C12N9/485 ,  C12N15/8214 ,  C12N15/8257 ,  C12Y304/15001 ,  C12Y304/17023 ,  C07K2319/55 ,  Y02A50/30

摘要： Emerging evidence indicates that diminished activity of the vasoprotective axis of the renin-angiotensin system, constituting angiotensin converting enzyme2 (ACE2) and its enzymatic product, angiotensin-(1-7) [Ang-(1-7)] contribute to pulmonary hypertension (PH). However, clinical success for long-term delivery of ACE2 or Ang-(1-7) would require stability and ease of administration to increase patient compliance. Chloroplast expression of therapeutic proteins enables their bioencapsulation within plant cells to protect from acids and gastric enzymes; fusion to a transmucosal carrier facilitates effective systemic absorption. Oral feeding of rats with bioencapsulated ACE2 or Ang-(1-7) attenuated monocrotaline (MCT)-induced increase in right ventricular systolic pressure, decreased pulmonary vessel wall thickness and improved right heart function in both prevention and reversal protocols. Furthermore, combination of ACE2 and Ang-(1-7) augmented the beneficial effects against cardio-pulmonary pathophysiology induced by MCT administration.
Experiments have also been performed which indicate that this approach is also suitable for the treatment or inhibition of experimental uveitis and autoimmune uveoretinitis These studies provide proof-of-concept for a novel low-cost oral ACE2 or Ang-(1-7) delivery system using transplastomic technology for pulmonary and ocular disease therapeutics.

公开(公告)号：US11945853B2

公开(公告)日：2024-04-02

申请号：US17839815

申请日：2022-06-14

申请人： UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED

发明人： Qiuhong Li ,  Mohan Raizada

IPC分类号： C07K14/575 ,  A61K35/00 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61K48/00 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/48

CPC分类号： C07K14/575 ,  A61K35/74 ,  A61K35/741 ,  A61K35/747 ,  A61K45/06 ,  A61P3/00 ,  A61P3/10 ,  A61P9/12 ,  A61P27/02 ,  A61P29/00 ,  C07K7/14 ,  C07K14/195 ,  C07K14/28 ,  C07K14/47 ,  C07K19/00 ,  C12N1/00 ,  C12N9/485 ,  A61K2035/115 ,  A61K48/00 ,  C07K2319/02 ,  C07K2319/50 ,  C07K2319/60

摘要： Provided herein are polynucleic acids and expression vectors for the expression and secretion of angiotensin peptide fragments (e.g., angiotensin-(1-7)) in probiotic bacteria. Provided herein are also probiotic compositions that enable efficient, cost-effective and patient friendly oral therapeutics for treating diverse pathological conditions that involve the renin-angiotensin system (RAS), e.g., pulmonary hypertension, diabetes, diabetic complications, cardiovascular diseases, and ocular inflammatory and neurodegenerative diseases.

公开(公告)号：US11684643B2

公开(公告)日：2023-06-27

申请号：US16486803

申请日：2018-02-19

申请人： The University of British Columbia

发明人： Deanna Gibson ,  Artem Godovannyi ,  Sandeep Gill

IPC分类号： A61K35/747 ,  A61K35/741 ,  C07K14/255 ,  C07K14/24 ,  C07K14/28 ,  A61K35/00 ,  A61P1/00 ,  C07K14/195 ,  C07K14/335

CPC分类号： A61K35/747 ,  A61K35/741 ,  A61P1/00 ,  C07K14/195 ,  C07K14/24 ,  C07K14/255 ,  C07K14/28 ,  C07K14/335 ,  A61K2035/115

摘要： The present invention relates to probiotic compositions. More specifically, the present invention relates to probiotic compositions that are useful in reducing inflammation and/or that exhibit increased colonization or persistence in the gastrointestinal tract of a mammal.

公开(公告)号：US20220265804A1

公开(公告)日：2022-08-25

申请号：US17594741

申请日：2020-03-13

申请人： ACADEMY OF MILITARY MEDICAL SCIENCES

发明人： Hengliang WANG ,  Chao PAN ,  Li ZHU ,  Jun WU ,  Jing HUANG ,  Lulu ZHANG ,  Peng SUN ,  Ming ZENG ,  Bin WANG ,  Xiankai LIU ,  Dongshu WANG ,  Erling FENG ,  Bo LIU

IPC分类号： A61K39/095 ,  A61K39/385 ,  A61P31/04 ,  C07K14/245 ,  C07K14/25 ,  C07K14/28 ,  C07K14/32

摘要： The present invention relates to a recombinant fusion protein and a polysaccharide conjugate vaccine. More specifically, the present invention relates to a fusion protein including a pentamer substrate protein and a peptide sequence capable of forming a trimer, an immunogenic composition including the fusion protein, the application of the fusion protein in immunology, a polynucleotide sequence encoding the fusion protein, an expression vector containing the polynucleotide sequence, and a host cell containing the expression vector.

公开(公告)号：US11071779B2

公开(公告)日：2021-07-27

申请号：US16310544

申请日：2017-06-16

申请人： Children's Medical Center Corporation

发明人： Paula I. Watnick ,  Szu Yu Liao

IPC分类号： A61K39/02 ,  A61K39/00 ,  A61K39/39 ,  C07K14/28 ,  C12N1/20

摘要： Some aspects of this disclosure provide engineered exopolysaccharide-associated proteins, engineered bacteria expressing such proteins, and engineered biofilms comprising such proteins. Some aspects of this disclosure provide methods for engineering exopolysaccharide-associated proteins, and for the generation of engineered bacteria and biofilms expressing or comprising such proteins. Some aspects of this disclosure provide compositions and methods useful for the generation of vaccines and the vaccination of subjects, for delivering molecules of interest to a target site, for example, a surface, for purification of molecules of interest, for example, from bioreactors comprising engineered bacteria as provided herein, and for bioremediation applications, such as the cleanup of environmental pollutants.

公开(公告)号：US20210170018A1

公开(公告)日：2021-06-10

申请号：US17122627

申请日：2020-12-15

申请人： The Governors of the University of Alberta ,  Helmholtz Center for Infection Research

发明人： Michael Houghton ,  Abdolamir Landi ,  Carlos A. Guzman ,  Thomas Ebensen ,  Darren Hockman ,  John L. Law ,  Michael Logan

IPC分类号： A61K39/29 ,  C07K14/18 ,  C07K14/33 ,  C12N15/86 ,  C01F11/02 ,  C07D323/00 ,  C07K14/34 ,  A61K39/39 ,  A61P31/14 ,  A61K39/12 ,  A61P37/04 ,  C07K14/28 ,  C07K14/005 ,  A61K39/00

摘要： The present disclosure provides immunogenic compositions comprising: a) hepatitis C virus (HCV) E1E2 heterodimers, HCV E2, or HCV E1; and b) an adjuvant, where the adjuvant is a cyclic dinucleotide or an archaeosome. The present disclosure provides methods of inducing an immune response in an individual to HCV, the methods comprising administering to an individual an effective amount of an immunogenic composition of the present disclosure.

公开(公告)号：US10987415B2

公开(公告)日：2021-04-27

申请号：US16061853

申请日：2016-12-09

申请人： MSD WELLCOME TRUST HILLEMAN LABORATORIES PVT. LTD.

发明人： Tarun Sharma ,  Neeraj Joshi ,  Vibhu Kanchan ,  Deepa Sikriwal ,  Nidhi Shukla ,  Davinder Gill

IPC分类号： C12N1/00 ,  A61K39/106 ,  A01N65/00 ,  A01N63/00 ,  A61K39/02 ,  C07K14/28 ,  C12P21/02 ,  A61P31/04 ,  C12P1/04 ,  A61K39/00 ,  C12N15/86 ,  C12N1/20

摘要： The present invention relates to a novel process of production of purified recombinant cholera toxin B (rCTB) which provides protection against diarrhea caused by various bacteria such as Vibrio cholerae and Enterotoxigenic Escherichia coli (ETEC). More particularly, the present invention relates to a process of production of rCTB with significantly higher yield and higher purity. The present invention also relates to a vaccine formulation having synergistic protection against Vibrio cholerae and cross protection against ETEC.

公开(公告)号：US10954520B2

公开(公告)日：2021-03-23

申请号：US16826929

申请日：2020-03-23

申请人： The Hospital for Sick Children

发明人： Roman A. Melnyk ,  Anick Auger ,  Greg Beilhartz ,  Berge Minassian ,  Seiji Sugiman-Marangos

IPC分类号： A61K39/00 ,  A61K39/02 ,  C07H21/04 ,  C12N15/62 ,  A61K35/74 ,  C07K14/34 ,  C07K14/28 ,  C07K14/33 ,  C07K14/47 ,  C07K14/475 ,  C12N9/10 ,  C12N9/22 ,  C12N9/28 ,  C12N9/52 ,  A61P35/00 ,  C07K14/45 ,  A61K38/45 ,  A61K38/48 ,  A61K47/68 ,  A61K47/42 ,  C07K7/08 ,  C07K14/00 ,  C07K16/12 ,  C12N11/06 ,  A61K38/00

摘要： There is a need for delivery platforms with robust capacity that offer the possibility to deliver diverse protein-based therapeutics into specific cells. Described herein is a platform for delivering cargo polypeptides into cells, which is based on a recombinant molecule comprising: a cargo polypeptide, a diphtheria toxin enzymatic fragment (DTA), and a diphtheria toxin translocation fragment (DTB). The platform has been employed to deliver diverse cargo into cells, including those having low or high molecular weights. A hyper-stable cargo polypeptide has been delivered, as well as proteins of therapeutic significance (e.g, MecP2, SMN, FMRP, PNP, alpha-amylase, RRSP, GRA16, and GRA24). The platform is also useful for delivering genome-modifying proteins, such as the CRISPR protein, Cas9. Associated nucleic acids, pharmaceutical compositions, methods, uses, and kits are also described, including those of therapeutic significance aimed at treating diseases or disorders caused by enzyme or protein deficiency, such as cancer.

公开(公告)号：US20210038708A1

公开(公告)日：2021-02-11

申请号：US16997186

申请日：2020-08-19

申请人： University of Louisville Research Foundation, Inc.

发明人： Nobuyuki Matoba ,  Keegan Baldauf ,  Joshua Royal

IPC分类号： A61K39/02 ,  C07K14/28 ,  A61K39/39

摘要： Protein complex variants, compositions, and methods of use thereof are provided. The protein complex variant includes a cholera toxin B subunit variant having one or more modifications thereto. The method of use thereof includes treating a disease by administering an effective amount of a composition including a cholera toxin B subunit variant to a subject in need thereof.

公开(公告)号：US10738127B2

公开(公告)日：2020-08-11

申请号：US16308443

申请日：2017-06-12

申请人： VERITAS BIOTECNOLOGIA LTDA

发明人： Sandra Rodrigues Pereira Faça ,  Vitor Marcel Faça

IPC分类号： C07K16/00 ,  A61K39/395 ,  C07K16/28 ,  A61P35/00 ,  C07K14/28 ,  C07K16/32 ,  C12N5/12 ,  G01N33/574 ,  A61K39/00

摘要： The present invention provides antibodies that target an E-cadherin linker segment, homologous to other segments adjacent to cell membrane in cancer cell shed proteins for diagnosis and therapy of cancers of epithelial origin. We design this peptide based in experimental observations that demonstrate shedding of E-cadherin and extracellular domains of other cell surface proteins during cancer progression and metastasis and based on our observation that a proline residue after transmembrane domain is present in many proteins on the cell surface that are targets for proteolytic processing. The corresponding antibodies were validated in vitro and in vivo using animal models and have showed no toxicity and significant tumor regression for gastric cancer, including potentiation of commercial drug, when utilized in combination.